Selective dopamine D2/D3 receptor antagonist (Ki values are 0.50 and 0.16 nM respectively). Antipsychotic.
|Storage||Desiccate at RT|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions
The following data is based on the product molecular weight 377.31. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||2.65 mL||13.25 mL||26.5 mL|
|5 mM||0.53 mL||2.65 mL||5.3 mL|
|10 mM||0.27 mL||1.33 mL||2.65 mL|
|50 mM||0.05 mL||0.27 mL||0.53 mL|
References are publications that support the products' biological activity.
Hall et al (1985) Some in vitro receptor binding properties of [3H]eticlopride, a novel substituted benzamide, selective for dopamine-D2 receptors in the rat brain. Eur.J.Pharmacol. 111 191 PMID: 4018125
Giuliani and Ferrari (1997) Involvement of dopamine receptors in the antipsychotic profile of (-) eticlopride. Physiol.Behav. 61 563 PMID: 9108576
Claytor et al (2006) The effects of eticlopride and the selective D3-antagonist PNU 99194-A on food- and cocaine-maintained responding in rhesus monkeys. Pharmacol.Biochem.Behav. 83 456 PMID: 16631246
If you know of a relevant reference for Eticlopride hydrochloride, please let us know.
View Related Products by Product Action
Keywords: Eticlopride hydrochloride, supplier, Selective, antagonists, D3, D2, Dopamine, D2-like, Non-Selective, Receptors, dopaminergic, (-)-Eticlopride, Non-selective, Dopamine, D3, Receptors, Non-selective, Dopamine, Tocris Bioscience
6 Citations for Eticlopride hydrochloride
Citations are publications that use Tocris products. Selected citations for Eticlopride hydrochloride include:
Cassar et al (2015) A dopamine receptor contributes to paraquat-induced neurotoxicity in Drosophila. J Ginseng Res 24 197 PMID: 25158689
Burgess et al (2010) Dopaminergic regulation of sleep and cataplexy in a murine model of narcolepsy. Sleep 33 1295 PMID: 21061851
Tønnesen et al (2011) Functional integration of grafted neural stem cell-derived dopaminergic neurons monitored by optogenetics in an in vitro Parkinson model. PLoS One 6 e17560 PMID: 21394212
Zhao et al (2014) Korean Red Ginseng attenuates anxiety-like behavior during ethanol withdrawal in rats. Neuropsychopharmacology 38 256 PMID: 25379005
Kramar et al (2014) Dopamine in the dorsal hippocampus impairs the late consolidation of cocaine-associated memory. Int J Neuropsychopharmacol 39 1645 PMID: 24442095
Jensen (2015) Effects of Dopamine D2-Like Receptor Antagonists on Light Responses of Ganglion Cells in Wild-Type and P23H Rat Retinas. PLoS One 10 e0146154 PMID: 26717015
Do you know of a great paper that uses Eticlopride hydrochloride from Tocris? If so please let us know.
Reviews for Eticlopride hydrochloride
There are currently no reviews for this product. Be the first to review Eticlopride hydrochloride and earn rewards!
Have you used Eticlopride hydrochloride?
Submit a review and receive an Amazon gift card.
$10US/$10CAN/€7/£6 gift card for a review without an image
$25US/$25CAN/€18/£15 gift card for a review with an image
*Offer only valid in the USA / Canada, UK and EuropeSubmit a Review
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* or download your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Dopamine Receptors Scientific Review
Written by Phillip Strange and revised by Kim Neve in 2013, this review summarizes the history of the dopamine receptors and provides an overview of individual receptor subtype properties, their distribution and identifies ligands which act at each receptor subtype. Compounds available from Tocris are listed.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.
Schizophrenia is a debilitating psychiatric disorder that affects 1% of the worldwide population. This poster describes the neurobiology of Schizophrenia, as well as highlighting the genetic and environmental factors that play a fundamental role in the etiology of the disease. The current and emerging drug targets are also discussed.